---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-006471"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T21:56:17.024812+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma Q3 fiscal 2025 revenue $14.4M (-8% YoY); operating profit $1.1M (-69%)

## Summary
- Consolidated revenue $14.4M for quarter ended Dec 31, 2024, down 8% from $15.6M in prior-year period.
- Operating profit fell 69% to $1.1M from $3.5M; company cites year-end holiday shipment delays.
- Shipments delayed into first week of January 2025 due to timing differences at December holiday period.
- No EPS, net income, or updated guidance provided in the release; conference call scheduled Feb 14.

## SEC filing metadata
- accession: 0001493152-25-006471
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315225006471/0001493152-25-006471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315225006471/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-006471
- JSON: https://secwatch.observer/filing/0001493152-25-006471.json
- Plain text: https://secwatch.observer/filing/0001493152-25-006471.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.